Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Royalty Pharma plc RPRX

Healthcare Biotechnology
Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The Company collaborates with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio consists of royalties on over 35 commercial products, including... see more

Recent & Breaking News (NDAQ:RPRX)

Mid-Day Market Update: Crude Oil Up 3.5%; Tractor Supply Shares Decline Following Weak Forecast

Benzinga.com  September 8, 2016

18 Stocks Moving In Thursday's Pre-Market Session

Benzinga.com  September 8, 2016

Repros Provides Phase 2 Results Showing Positive Outcomes for Oral Proellex® in Women With Moderate to Severe Endometriosis

GlobeNewswire September 7, 2016

Repros Provides Six Month Interim Results for Enclomiphene Study in Obese Secondary Hypogonadal Men

GlobeNewswire August 15, 2016

Repros Therapeutics Inc.® Reports Second Quarter 2016 Financial Results

GlobeNewswire August 9, 2016

Mid-Afternoon Market Update: U.S. Stocks Turn Positive; American Woodmark Shares Fall On Earnings Miss

Benzinga.com  June 2, 2016

Mid-Morning Market Update: Markets Open Lower; Joy Global Profit Tops Expectations

Benzinga.com  June 2, 2016

Report: Snapchat Now Has More Daily Users Than Twitter

Benzinga.com  June 2, 2016

Repros Provides Update on EU Submission of Enclomiphene for the Treatment of Secondary Hypogonadism and 3 Month Interim Results for Enclomiphene Study in Obese Secondary Hypogonadal Men

GlobeNewswire June 1, 2016

Repros Reports Positive Clinical Data for Oral Proellex® in Women With Severe Menstrual Bleeding Due to Uterine Fibroids

GlobeNewswire May 18, 2016

Repros Announces the Appointment of Mr. Patrick Fourteau as Chairman of the Board

GlobeNewswire May 16, 2016

Repros Therapeutics Inc.® Reports First Quarter 2016 Financial Results

GlobeNewswire May 10, 2016

Trending Stocks: Investors Have Found Interest In These Four Nasdaq Stocks on Monday

Accesswire April 18, 2016

Trending Stocks: Thursday's Top Trading Stock Investors Have Followed

Accesswire April 14, 2016

Repros Therapeutics (RPRX) Announces Significant Data for Proellex Phase 2 Meeting with the FDA to Jointly Discuss Plans for Phase 3

Accesswire April 13, 2016

Repros Reports Positive Clinical Data for Vaginal Proellex® in Women With Severe Menstrual Bleeding Due to Uterine Fibroids

GlobeNewswire April 12, 2016

Repros Announces Initiation of Formal Approval Process by the European Medicines Agency

GlobeNewswire March 15, 2016

Repros Therapeutics Inc.® Reports Fourth Quarter and Year End 2015 Financial Results

GlobeNewswire March 14, 2016

Repros Completes Randomization of Enclomiphene Phase 2 Proof of Concept Study in Obese Secondary Hypogonadal Men

Press Releases February 16, 2016

Repros Holds Meeting With FDA to Discuss Complete Response Letter for Enclomiphene in the Treatment of Secondary Hypogonadism

GlobeNewswire February 8, 2016